Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 5/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | KHK | P50053 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24958943 | 0.92 | IRAK4 (0.49) | NTRK1PIM1IRAK4METJAK2 | |
| SCHEMBL24958704 | 0.88 | PIM1 (0.54) | NTRK1PIM1IRAK4METJAK2 | |
| SCHEMBL24956536 | 0.74 | MET (0.49) | NTRK1IRAK4METJAK2JAK1 | |
| SCHEMBL24958700 | 0.74 | MET (0.40) | PIM1IRAK4METCHRNB2CHRNA4 | |
| SCHEMBL24958882 | 0.70 | JAK2 (0.48) | NTRK1PIM1METJAK2JAK1 | |
| SCHEMBL24958944 | 0.69 | CHRNB2 (0.40) | PIM1IRAK4MAP3K12CHRNB2CHRNA4 | |
| SCHEMBL24958907 | 0.69 | PIM1 (0.53) | NTRK1PIM1IRAK4JAK2JAK1 | |
| SCHEMBL24151179 | 0.69 | ASIC3 (0.47) | PIM1MAP3K12METJAK2PIM3 | |
| SCHEMBL26352019 | 0.69 | JAK2 (0.50) | PIM1IRAK4CHRNB2CHRNA4JAK2 | |
| SCHEMBL17806588 | 0.68 | PIK3CD (0.46) | KDM5BIRAK4CHRNB2CHRNA4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | NTRK1 2206/4885KDM5B 2572/4885PIM1 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.